top of page
PATHFINDER
OFFICIAL TITLE: A MULTICENTER, OPEN-LABEL, NON-COMPARATIVE, THREE-ARM, PHASE IIa TRIAL OF IPATASERTIB (GDC-0068) IN COMBINATION WITH NON-TAXANE CHEMOTHERAPY AGENTS FOR TAXANE-PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER PATIENTS (PATHFINDER)
CLINICAL TRIAL DETAILS
THIS IS A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE 3-ARM CLINICAL TRIAL. THE STUDY WILL BE DIVIDED INTO TWO STAGES: A SAFETY RUN-IN PART FOLLOWED BY A NON-RANDOMIZED PHASE IIA STAGE AS AN EXPANSION STUDY.
PRIMARY GOAL WANTS TO EVALUATE THE SAFETY AND TOLERABILITY OF IPATASERTIB (GDC-0068) IN COMBINATION WITH CAPECITABINE, ERIBULIN, OR CARBOPLATIN PLUS GEMCITABINE IN THE INTENTION-TO-TREAT (ITT) POPULATION OF PATIENTS WITH TAXANE-PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC).
THE SECONDARY GOAL WANTS TO DETERMINE THE EFFICACY OF IPATASERTIB (GDC-0068) IN COMBINATION WITH CAPECITABINE, ERIBULIN, OR CARBOPLATIN PLUS GEMCITABINE IN THE ITT POPULATION AND IN EACH TREATMENT ARM.
PATHFINDER AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TNBC
IIa
54
20
Spain, Portugal
Recruiting
PRESS RELEASE
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
ESMO 2021: - DOWNLOAD THE ABSTRACT
TRIAL RESUME
PATHFINDER SITES
SPAIN
IOB - Hospital QuironSalud Barcelona
SPAIN
Hospital Universitario Ramon y Cajal
SPAIN
Arnau de Vilanova de Valencia
SPAIN
Ruber Juan Bravo/Hospital Quiron San Camilo
SPAIN
Hospital Miguel Servet
SPAIN
Hospital Universitari Arnau de Vilanova de Lleida
SPAIN
Hospital Virgen de Arrixaca
SPAIN
Hospital General de Alicante
SPAIN
Hospital Universitario San Pedro de Alcántara
SPAIN
Hospital Provincial de Castellón
SPAIN
Hospital Clínico Universitario de Valencia
SPAIN
Hospital del Mar
SPAIN
Hospital Clinico Universitario Virgen de la Victoria de Malaga
PORTUGAL
Champalimaud Clinical Center
PORTUGAL
IPO Porto
bottom of page